YPrime in Action: An Osteogenesis Imperfecta (OI) Study
A biotech company needed assistance with a gene therapy trial for osteogenesis imperfecta (OI). OI is a rare disease caused by faulty genes that impact collagen production. Faced with the task of incorporating the POSNA-PODCI and site-reported fracture form without tablets, the company sought YPrime’s eCOA expertise and industry-leading platform to streamline data collection and enable regulatory compliance.
YPrime delivered several advanced, configurable questionnaires and functionalities for at-home data collection under caregiver supervision. Dual functionality on handheld devices provided both instruments for clinical visits and bring-your-own-device (BYOD) options, enhancing patient and caregiver convenience. Event-based diaries allowed caregivers to document fracture events in real-time, alongside a site-reported fracture feature for in-office visit data capture.
YPrime’s flexible and highly configurable eCOA platform addressed the biotech company’s immediate needs and set a new standard for conducting rare disease studies.
This case study showcases YPrime’s ability to:
Download the case study to learn more.